What is Scopio?
Scopio Labs is fundamentally redefining the landscape of cell morphology analysis through its proprietary, fully digital diagnostic applications. By integrating high-resolution imaging with advanced AI-powered decision support systems, the company enables laboratories to conduct deep-scale analysis with unprecedented efficiency. This technological leap facilitates faster, more accurate disease detection, ultimately improving patient outcomes across the continuum of care. With FDA-cleared and CE-marked applications already in commercial use, Scopio is effectively bridging the gap between traditional microscopy and the future of digital pathology, providing clinicians with the tools necessary for consistent and reliable diagnostic results.
How much funding has Scopio raised?
Scopio has raised a total of $118M across 3 funding rounds:
Series B
$16M
Series C
$50M
Series D
$52M
Series B (2020): $16M with participation from OurCrowd, LR group, Aurum Ventures Private, and Olive Tree Ventures
Series C (2022): $50M led by Aurum, OurCrowd, Bank Mizrahi-Tefahot, and Ilex Medical
Series D (2025): $52M supported by Viola Group and Fortissimo
Key Investors in Scopio
Viola Group
Viola Group is Israel's leading technology investment group, managing over $6 billion in assets and supporting transformational companies through a multi-strategy approach.
Fortissimo
Fortissimo Capital is a prominent private equity fund specializing in technology and industrial sectors, focusing on proactive growth and strategic buyouts.
OurCrowd
OurCrowd is a global investment platform that connects accredited investors and institutions with high-growth startups and venture funds.
What's next for Scopio?
With the successful closure of this major strategic investment, Scopio is well-positioned to scale its commercial operations and expand its footprint in the global diagnostics market. The company's roadmap likely includes the further development of its AI-powered diagnostic suite and the potential expansion of its application portfolio beyond peripheral blood smears and veterinary diagnostics. As Scopio continues to integrate its platforms into hospital and laboratory workflows, the focus will remain on enhancing diagnostic precision and reducing the time-to-treatment for patients worldwide. This capital injection provides the necessary runway to solidify its market leadership and drive long-term innovation in the digital health ecosystem.
See full Scopio company page
